EUVIMEDEUVIMED entdecken
Crossref

Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery

Xueyang Zhang, Ludan Yue, Lei Cao, Kun Liu, Shengren Yang, Shuang Liang, Lujie Liu, Chenchen Zhao, Dudu Wu, Zhaohui Wang, Rui Tian, Lang Rao

Acta Biomaterialia · 2024

DOI: 10.1016/j.actbio.2024.07.042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2024. Verfasst von Xueyang Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Research and Application Center of Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China; Shenzhen …. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy, as a promising treatment strategy for cancer, has been widely employed in clinics, while its efficiency is limited by the immunosuppression of tumor microenvironment (TME). Tumor-associate macrophages (TAMs) are the most abundant immune cells infiltrating the TME and play a crucial role in immune regulation. Herein, a M0-type macrophage-mediated drug delivery system (PR-M) was designed for carrying Toll-like receptors (TLRs) agonist-loaded nanoparticles. When TLR agonist R848 was released by responding to the TME, the PR-Ms were polarized from M0-type to M1-type and TAMs were also stimulated from M2-type to M1-type, which eventually reversed the immunosuppressive states of TME. By synergizing with the released R848 agonists, the PR-M significantly activated CD4+ and CD8+ T cells in the TME and turned the 'cold' tumor into 'hot' tumor by regulating the secretion of cytokines including IFN-γ, TNF-α, IL-10, and IL-12, thus ultimately promoting the activation of antitumor immunity. In a colorectal cancer mouse model, the PR-M treatment effectively accumulated at the tumor site, with a 5.47-fold increase in M1-type and a 65.08 % decrease in M2-type, resulting in an 85.25 % inhibition of tumor growth and a 87.55 % reduction of tumor volume compared with the non-treatment group. Our work suggests that immune cell-mediated drug delivery systems can effectively increase drug accumulation at the tumor site and reduce toxic side effects, resulting in a strong immune system for tumor immunotherapy. STATEMENT OF SIGNIFICANCE: The formation of TME and the activation of TAMs create an immunosuppressive network that allows tumor to escape the immune system and promotes its growth and spread. In this study, we designed an M0-type macrophage-mediated drug delivery system (PR-M). It leverages the synergistic effect of macrophages and agonists to improve the tumor immunosuppressive micro-environment by increasing M1-type macrophages and decreasing M2-type macrophages. As part of the treatment, the drug-loaded macrophages endowed the system with excellent tumor targeting. Furthermore, loading R848 into TME-responsive nanoparticles could protect macrophages and reduce the potential toxicity of agonists. Further investigations demonstrated that the designed PR-M could be a feasible strategy with high efficacy in tumor targeting, drug loading, autoimmunity activation, and lower side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentImmunotherapyAnimalsMiceMacrophagesDrug Delivery SystemsRAW 264.7 CellsImidazolesCell Line, TumorNanoparticlesTumor-Associated MacrophagesToll-Like ReceptorsMice, Inbred BALB CHumansFemaleMice, Inbred C57BLCytokines

Stichwörter der Autor:innen

ImmunotherapyMacrophage-mediate drug deliveryRepolarizationTumor microenvironmentTumor-associate macrophage

Substanzen

resiquimodImidazolesToll-Like ReceptorsCytokines

Autor:innen und Institutionen

  • The Research and Application Center of Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China; Shenzhen Bay Laboratory, Shenzhen 518132, China; School of Pharmacy, Guangdong…
  • Shenzhen Bay Laboratory, Shenzhen 518132, China.
  • School of Pharmacy, Guangdong Medical University, Dongguan, Guangdong 523808, China.
  • State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, China.
  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
  • The Research and Application Center of Precision Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450014, China; Shenzhen Bay Laboratory, Shenzhen 518132, China.

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Zhang, X., Yue, L., Cao, L., Liu, K., Yang, S., Liang, S., Liu, L., Zhao, C., Wu, D., Wang, Z., Tian, R., & Rao, L. (2024). Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2024.07.042

Vancouver

Zhang X, Yue L, Cao L, Liu K, Yang S, Liang S, et al. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery. Acta Biomaterialia. 2024. doi:10.1016/j.actbio.2024.07.042

BibTeX
@article{Zhang2024,
  author = {Zhang, Xueyang and Yue, Ludan and Cao, Lei and Liu, Kun and Yang, Shengren and Liang, Shuang and Liu, Lujie and Zhao, Chenchen and Wu, Dudu and Wang, Zhaohui and Tian, Rui and Rao, Lang},
  title = {Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery},
  journal = {Acta Biomaterialia},
  year = {2024},
  doi = {10.1016/j.actbio.2024.07.042}
}
Kostenlos starten →